The three Managing Directors are the sole owners of Destum Partners. Over forty years of industry experience carefully guides the successful implementation of our services to benefit our Clients. An invaluable combination of skill sets including commercial, marketing, financial, IP, and transactional expertise are infused into our firm through the Managing Directors, consequently positioning Destum Partners as a premier Advisory and Consulting firm to the Biopharmaceutical and Life Sciences industries.
Gareth Lugg, MBA
Co-Founder & Managing Director
Prior to starting Destum Partners, Gareth worked for major financial institutions such as Morgan Stanley and Smith Barney. Throughout his career, Gareth has worked with companies pushing the envelopes of science, technology, and commercial strategy. He has worked with a wide array of companies ranging from start-ups to major pharma.
Gareth has completed approximately $2B worth of licensing and M&A transactions. Recently, Gareth led the successful in-license of Giapreza and Xerava from La Jolla Pharma to Paion AG in a deal worth over $130M. He has represented Destum Partners in several deals including: Deals on behalf of Hammock Pharma, MEI Pharma, Advaxis, Inc., Antisense Therapeutics & Cortendo, Athersys & Chugai, Wilex & Link Health Group, and Diamyd & OMJPI (J&J).
In addition, Gareth plays a critical role in managing multiple engagements within Destum Partners consulting practice. Gareth has provided strategic guidance to a variety of companies including Inveready, UCB Pharma, Pieris AG, Cempra Pharmaceuticals, Arena Pharmaceuticals, Advaxis, and several others.
Gareth received a B.S. in Biology from Queens University and a Masters in Business Administration (MBA) from Queens University with concentrations in Finance and Marketing.
Managing Director & PARTNER
Mr. Filipczak is a Managing Director and has been with Destum Partners since the company’s inception. Tom is exclusively focused in the biopharma sector, and is responsible for selecting and executing upon numerous advisory as well as consulting mandates for companies ranging from small biotech to major pharmaceutical companies. He has represented Destum Partners in several deals including: SIFI & Knight Therapeutics, InnoPharmax & AVIR, Athersys & Chugai, as well as other licensing and distribution transactions throughout the globe. Tom has provided strategic insight to Sandoz, Dr. Reddy’s, Chimerix, Zealand Pharma, Cempra Pharmaceuticals, and Arena Pharmaceuticals, to name a few.
Mr. Filipczak has over 25 years in the pharmaceutical and biotech arena, including 16 years commercial experience in various therapeutic areas with emphasis in Orphan Drugs and Rare diseases, specifically in transplantation, immunology, infectious disease, and oncology. His background includes new business development, medical affairs, strategic initiatives, and expertise in product launches. Before joining Destum Partners, Mr. Filipczak worked as Regional Sales Manager for Vicuron Pharmaceuticals. At Vicuron, he deployed a sales team for the launch of two proprietary compounds, ERAXIS™ (anidulafungin) and Zeven™ (dalbavancin), before being acquired by Pfizer. Prior to working at Vicuron, Mr. Filipczak was a Regional Sales Manager at Roche Pharmaceuticals where he successfully launched the transplantation and infectious disease portfolio including CellCept®, Zenapax®, Cytovene®, Valcyte®, and Pegasys®. He developed several strategies and tactics to ensure growth of the franchise to the peak level at Roche. His pharmaceutical career began with Sandoz (Novartis) Pharmaceuticals with positions of increased responsibility in primary care, specialty care, and the hospital market places.
Mr. Filipczak holds a Bachelors Degree in Business Administration with majors in Finance and Management from Indiana University School of Business.
Managing Director & PARTNER
Matthew Vanderberg is a Managing Director of Destum Partners and has been with the company since its inception. Mr. Vanderberg oversees the life sciences sector yet also plays an active role within the execution of the biopharma sector. Mr. Vanderberg is responsible for the identification, evaluation and selection of novel technologies to integrate within the Destum Partners portfolio. Mr. Vanderberg has successfully bridged the sector technology gap by introducing technologies from the biopharma sector to companies seeking technologies within the animal health, animal nutrition, and functional food sectors.
Mr. Vanderberg’s background is a combination of business and transactional management in the chemical and financial sectors. Mr. Vanderberg brings to Destum Partners fifteen years of transactional experience across a multitude of disciplines. His work with clients has ranged from small start-up organizations to large Fortune 500 companies such as Pfizer, Kraft Foods Inc., Colgate Palmolive, GlaxoSmithKline, Orion, Ecolab and SAS Institute. Mr. Vanderberg previously held positions with Wachovia and Bank of America where he specialized in financial forecasting and analysis. Additionally, Mr. Vanderberg has been granted nine patents.
Mr. Vanderberg received a BA in International Business from the University of North Carolina-Charlotte.
Vice President, Business Development
Kate Bailey, Ph.D.
Allen Potter, Pharm.D.